GB1317400A — Process for producing pellets
Assigned to Sumitomo Chemical Co Ltd · Expires 1973-05-16 · 53y expired
What this patent protects
1317400 Medicinal pellets SUMITOMO CHEMICAL CO Ltd 15 June 1971 [15 June 1970 10 Dec 1970] 28008/71 Heading A5B [Also in Division B5] Pellets are formed from powders by adding binder liquid to granules and sprinkling these wet nuclear granules, onto the powders, the granules cons…
USPTO Abstract
1317400 Medicinal pellets SUMITOMO CHEMICAL CO Ltd 15 June 1971 [15 June 1970 10 Dec 1970] 28008/71 Heading A5B [Also in Division B5] Pellets are formed from powders by adding binder liquid to granules and sprinkling these wet nuclear granules, onto the powders, the granules consisting of at least one of synthetic colloidal silicon dioxide, synthetic silicate of aluminium or magnesium, aluminium hydroxide gel, aluminium hydroxide-magnesium hydroxide gel, aluminium hydroxide-aluminium carbonate gel, or magnesium aluminium hydroxide carbonate. The binder liquid may be water or an alcohol, and the powders may be for medical purposes, several examples being given. Known processes - and apparatus are used, e.g. the granules, which should be shaped and sized appropriately for the desired shape of pellet, may be placed in a vessel, binder liquid added and stirred then left standing and finally screened and blended. The powder is then put into a dish-type pelletizer and the wet granules sprinkled thereon by a vibration feeder during rotation of the pelletizer, rolling is continued for a period and the formed pellets are then dried and screened. The powder may be, or contain, a drum or adjuvant, and may also contain a surfactant, lubricant, binder, pH-adjusting agent, tastemasking agent, flavouring or colouring agent.
Drugs covered by this patent
- Tybost (COBICISTAT) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.